Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Betadex sulfobutyl ether sodium enabled IV voriconazole; Captisol-enabled IV voraconazole; SBECD enabled IV voriconazole; Sulphobutly ether beta cyclodextrin enabled IV voriconazole; UK-109496; Vfend

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antifungals; Pyrimidines; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidiasis; Fusariosis; Mycoses

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Aug 2015 No development reported - Phase-III for Candidiasis (In adolescents, In children) in Mexico, Czech Republic, Hong Kong, Hungary, Philippines, Poland, Slovakia, China (PO and IV)
  • 30 Sep 2013 First generic equivalent of Vfend® (PO, solution) available in USA for Mycoses
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top